Chevron’s Fall Strengthens Industry’s Hand In Disagreements With US FDA, But May Create Delays

Firms can be more forceful in disputes with FDA now that Supreme Court has eliminated Chevron deference. Questions around whether an evidentiary standard has been met may be ripe for challenge, legal experts said, but they also caution that sponsors will face more uncertainty.

Produce
What types of FDA disputes are ripe for litigation in a post-Chevron world? • Source: Shutterstock

[Editor's note: This story appeared first in our sister publication, Pink Sheet.]

Biopharma companies that have a prelitigation dispute with the US Food and Drug Administration will be in a stronger position...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Legal & IP

More from Policy & Regulation